Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors. METHODS: A patient-level sim...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Huoponen, Saara, Aaltonen, Kalle J., Viikinkoski, Jaana, Rutanen, Jarno, Relas, Heikki, Taimen, Kirsi, Puolakka, Kari, Nordström, Dan, Blom, Marja
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656352/
https://ncbi.nlm.nih.gov/pubmed/31339961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220142
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky